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Objectives: To compare receptor activator of NF-κB ligand (RANKL) production in the synovial tissue
from patients with active rheumatoid arthritis (RA), inactive RA, spondyloarthropathies (SpA),
osteoarthritis, and from normal subjects. In addition, to establish the cell lineages expressing RANKL in
these tissues.
Methods: Immunohistological analysis of frozen synovial tissue biopsy specimens was performed
using a monoclonal antibody (mAb) to detect RANKL. Sections were evaluated by computer assisted
image analysis and semiquantitative analysis to compare RANKL expression between groups. Dual
and sequential labelling with mAb RANKL and cell lineage specific monoclonal antibodies were used
to determine the types of cells expressing RANKL.
Results: Higher levels of RANKL were expressed in tissues from patients with active RA and SpA than
in tissues from patients with inactive RA, osteoarthritis, and from normal subjects. RANKL protein was
associated with CD3 antigen-positive lymphocytes and some macrophages. RANKL was predominantly
associated with activated, memory T cells (CD45Ro positive cells) in patients with active RA and
spondyloarthropathy (SpA).
Conclusions: The highest levels of RANKL were detected in patients with RA with active synovitis and
in some patients with SpA. An increase in RANKL in the inflamed joint of patients with RA, produced
by infiltrating activated T cells and macrophages, is likely to be an important cause of joint erosions in
RA.
Rheumatoid arthritis (RA) is a chronic inflammatorydisease characterised by articular cartilage and bonedestruction following growth of the inflamed synovial tis-
sue over the articular surface. Extensive bone erosion is often
seen as marginal joint erosions radiographically, and is
predictive of a poorer prognosis.1 This inflammation and tissue
destruction in RA is thought to involve cell-cell interactions
between lymphocytes,monocytes/macrophages, and type A and
B synoviocytes. These cell interactions result in the production
of matrix metalloproteinases, cathepsins, and mast cell protein-
ases that cause cartilage and bone destruction.2–4 Osteoclast for-
mation from cells of the macrophage/monocyte lineage at the
cartilage-pannus junction is associated with the destruction of
bone matrix in patients with RA.5–8
A number of inflammatory cytokines found in the RA
synovial fluid and tissue (interleukin (IL)1α and β, IL6,
tumour necrosis factor (TNF)α, macrophage colony stimulat-
ing factor) have the potential to promote osteoclast formation
and bone resorption.9–13 These may act by increasing produc-
tion of the receptor activator of NF-κB ligand (RANKL), a
recently identified primary mediator of osteoclastogenesis.14
RANKL and its receptor, RANK (receptor activator of NF-κB),
are key factors in osteoclast formation5 6 15 and regulation of
the immune system.16 RANKL is expressed by osteoblasts/
stromal cells,15 fibroblasts,5 6 17 and activated T cells5 18 19 and
binds directly to RANK on pre-osteoclasts and osteoclasts,
enabling signal transduction for the differentiation of
osteoclast progenitors as well as activation of mature
osteoclasts.15 20 21 In addition to their pivotal role in osteoclast
formation, RANKL and RANK have a role in immune cell dif-
ferentiation and T cell/dendritic cell interactions.16 22–24
Osteoprotegerin (OPG), a soluble TNF receptor-like mol-
ecule, is the naturally occurring inhibitor of RANKL. OPG acts
as a decoy soluble receptor preventing osteoclastogenesis by
binding to RANKL with high affinity, essentially blocking
RANKL from interacting with RANK both in vivo and in
vitro.20 25 26 The fundamental role of these molecules in
regulating bone morphology has been clearly demonstrated in
transgenic and knockout mice.16 25 27 28
We have reported mRNA expression of RANKL, RANK, and
OPG in cells isolated from RA joints and the significant corre-
lation between the number of resorption pits formed by cells
extracted from these tissues and the ratio of RANKL mRNA to
OPG mRNA.8 More recently, we found that the level of OPG
protein, detected in situ by immunohistochemistry, is mark-
edly decreased in patients with RA with active synovitis com-
pared with patients with inactive RA, osteoarthritis (OA), and
normal subjects.29 This study compared the protein expression
of RANKL in the synovial tissue from patients with active RA
with that seen in patients with inactive RA, spondyloarthropa-
thies, OA, and in normal subjects. A unique aspect of this
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study is the use of semiquantitative and quantitative
techniques to measure synovial tissue staining of RANKL pro-
tein in patients with a range of inflammatory and non-
inflammatory arthritides. Using this data, we aimed at testing
the hypothesis that RANKL protein is expressed at higher lev-
els in patients with RA with active disease than in synovial
tissue from patients with inactive RA or other arthritides.
In addition, we used dual immunohistochemical labelling
techniques and sequential staining to verify the cell lineages
expressing RANKL in these tissues. This enabled us to investi-
gate the controversial role of T cells and macrophages in the
localised bone loss associated with RA.
PATIENTS AND METHODS
Patients
Thirty patients with RA (21 with active synovitis in a knee
joint and nine with no evidence of any synovitis) and 12
patients with a spondyloarthropathy (SpA) and active synovi-
tis of a knee joint were investigated together with seven
patients with OA of the knee joint and 18 normal subjects. All
patients with RA fulfilled the American College of Rheumatol-
ogy criteria for RA,30 while the patients with SpA fulfilled the
European Spondylarthropathy Study Group (ESSG) criteria
for the diagnosis of ankylosing spondylitis and Reiter’s
disease.31 Patients with psoriatic arthritis32 and OA of the
knee33 fulfilled published criteria. Table 1 summarises details
of the patients and drugs used at the time of surgery. The
study protocol was approved by the institutional medical eth-
ics committee under the condition that the patients included
gave their informed consent.
Synovial tissue
A small-bore arthroscopy (2.7 mm arthroscope; Dyonics,
Andover, Massachusetts, USA) was performed under local
anaesthesia as previously described.34 Biopsy specimens of
synovial tissue from patients with RA were obtained from all
accessible regions of the knee joint, but mainly from the
suprapatellar pouch. OA synovial tissue was obtained at the


















Patients with active RA
RA1 76 M 2 NSAIDs 59 + −
RA2 72 M 3 NSAIDs 120 + −
RA3 65 M 9 Plaquenil 30 + −
RA4 75 F 3 NSAIDs 47 + +
RA5 47 M 3 NSAIDs 58 + −
RA6 61 F 2 NSAIDs 84 − −
RA7 75 M 2 NSAIDs 20 − −
RA8 86 M 6 NSAIDs 76 − −
RA9 78 F 3 NSAIDs 27 + +
RA10 31 F 6 NSAIDs 32 + −
RA11 67 F 2 Prednisolone 307 − −
RA12 76 F 4 NSAIDs 89 − −
RA13 77 M 3 NSAIDs 62 + −
RA14 74 F 4 NSAIDs 46 + +
RA15 70 M 2 NSAIDs 116 + +
RA16 76 F 2 NSAIDs 32 − −
RA17 59 F 4 Plaquenil 82 − −
RA18 49 F 10 NSAIDs 35 − +
RA19 28 F 2 Sulphasalazine 37 − −
RA20 68 M 5 NSAIDs 34 + +
RA21 62 M 2 NSAIDs 28 − −
Patients with inactive RA
RA1 78 M 30 MTX <1 − −
RA2 79 M 24 IM gold 5 + −
RA3 75 F 16 MTX <1 + −
RA4 73 M 34 IM gold <1 + −
RA5 60 F 7 IM gold <1 − −
RA6 63 M 8 Plaquenil <1 − −
RA7 79 M 27 SSZ 2 + −
RA8 76 F 14 IM gold 5 − +
RA9 68 M 36 IM gold/ MTX 7 + +
Patients with SpA
SpA1 26 F 36 NSAIDs 22 − Psoriatic arthritis
SpA2 60 F 96 SSZ 58 − Psoriatic arthritis
SpA3 28 F 24 SSZ 13 + Reiter’s
SpA4 43 F 192 NSAIDs 48 + Reiter’s
SpA5 33 M 168 NSAIDs 45 + Reactive arthritis
SpA6 40 M 24 NSAIDs 13 − Psoriatic arthritis
SpA7 49 F 60 NSAIDS 45 − Psoriatic arthritis
SpA8 65 M 56 NSAIDs 26 − Psoriatic arthritis
SpA9 75 M 8 NSAIDs 94 + AS
SpA10 73 M 120 NSAIDs 73 + AS
SpA11 63 F 6 SSZ/AZA/prednisolone 52 + Colitic arthritis
SpA12 30 M 72 SSZ/NSAIDs 34 + AS
CRP, C reactive protein: RF, rheumatoid factor; RA, rheumatoid arthritis; NSAIDs, non-steroidal
anti-inflammatory drugs; MTX, methotrexate; IM gold, intramuscular sodium aurothiomalate; SpA,
spondyloarthropathy; SSZ, sulfasalazine; AS, ankylosing spondylitis; AZA, azathioprine.
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time of knee replacement surgery and normal synovial tissue
was obtained at the time of knee arthroscopy for unexplained
knee pain. The samples were separately snap frozen in Tissue-
Tek OCT (Miles Diagnostics, Elkhart, IN, USA) and stored at
−80°C until used. Sections (5 µm) were cut on a cryostat and
mounted on APTS (Sigma, St Louis, MO, USA) coated glass
slides. The glass slides were boxed and stored at −20°C until
immunohistological analysis.
Immunohistochemistry
Serial sections were stained with the following mouse mono-
clonal antibodies (mAb): antihuman RANKL antibody
Figure 1 RANKL detected with mAb 626/immunoperoxidase and AEC (red), in synovial tissue from a patient with RA with (A) active disease
and (B) inactive disease, (C) a patient with SpA, and (D) a patient with OA. (E) to (H) identify cell lineages expressing RANKL (mAb
626/immunoperoxidase (red)) using dual immunohistochemical labelling on serial synovial biopsy sections from a patient with RA with active
disease. RANKL expression is identified by mAb 626 using an AEC/immunoperoxidase technique combined with an immunohistochemical
alkaline phosphatase technique using fast blue to identify cell surface markers. (E) Dual labelling with anti-CD3 (blue) and both (purple), (F) B
cell antibody anti-CD22 (blue), (G) monocyte/macrophage lineage anti-CD68 (blue) and both (purple), (H) FLS with anti- CD55/fast blue
(blue). All magnifications taken at ×20.
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(MAB626; R&D Systems, Inc, Minneapolis, MN, USA) and
anti-CD68 (EBM11; DAKO) to detect macrophages; mAb 67
(Serotec, Kidlington, Oxford, UK), which recognises CD55, to
detect fibroblast-like synoviocytes (FLS); anti-CD22 (CLB) to
detect B cells; anti-CD3 (Becton Dickinson, CA, USA) to detect
pan-T cells; and anti-CD45Ro (UCHL1; DAKO, Denmark) for
activated, memory T cells. To eliminate variability in immuno-
histochemical staining, all sections to be stained with a
particular antibody were processed in the same run and the
antibody was left on for the same amount of time. The absence
of staining was identical to that obtained when a non-specific
primary antibody was used.35 In addition, blocking the activity
of the RANKL antibody by preincubation for 24 hours with
excess human recombinant RANKL (a gift from AMGEN Inc,
Thousand Oaks, CA, USA) nearly eliminated staining (data
not shown).
Endogenous peroxidase activity was inhibited by 0.1%
sodium azide and 1% hydrogen peroxide in Tris/phosphate
Figure 2 Panels (A), (C), (E), (G) demonstrate RANKL expression, detected with mAb 626/ immunoperoxidase and AEC (red), in synovial
tissue from a patient with RA with active disease (A), inactive disease (C), SpA (E), and from a normal subject (G). Panels (B), (D), (F), (H) show
sequential sections where CD45Ro is detected with immunoperoxidase and AEC (red) in synovial tissue from patients with active RA (B),
inactive RA (D), SpA (F), and from a normal subject (H). All magnifications taken at ×20.
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buffered saline buffer. After incubation with the primary mAb
RANKL 626 (or CD45Ro in a selection of samples from each
group) for 60 minutes, bound antibody was detected
according to a three step immunoperoxidase method.36 37 Sec-
tions were incubated with horseradish peroxidase (HRP) con-
jugated goat antimouse antibody, followed by incubation with
HRP conjugated swine antigoat antibody. HRP activity was
detected using hydrogen peroxide as the substrate and
3-amino-9-ethylcarbazole (AEC) as the dye. Slides were coun-
terstained briefly with haematoxylin solution and mounted in
Gurr Aquamount (BDH, Poole, UK). Affinity purified, HRP
conjugated goat antimouse antibody was obtained from
DAKO; affinity purified HRP, conjugated swine antigoat
immunoglobulin from Tago (Burlingame, CA, USA); and AEC
from Sigma (St Louis, MO, USA).
Dual immunohistochemistry
Dual immunohistochemical labelling was performed as previ-
ously described.38 39 In brief, the synovial tissue was incubated
with the first primary antibody (anti-RANKL) and subsequent
steps, in a standard three step immunoperoxidase method,
were performed, developing the final colour product using
AEC. Between the first and second immunohistochemical
reactions the tissue was washed and blocked with Tris-glycine
to prevent cross reaction between the first primary and the
second linking antibody. The second primary antibody
(anti-CD68, anti-CD55, anti-CD3, or anti-CD22) was placed on
the sections overnight at 4°C, followed by a standard
immunohistochemical alkaline phosphatase method,37 38 de-
veloping the colour reaction with fast blue. No counterstain
was used and the sections were mounted in an aqueous
mounting medium.
Microscopic analysis
After immunohistochemical staining, sections stained with
anti-RANKL were analysed in a random order by computer
assisted image analysis, with six high power fields for each
section analysed as previously published.36 37 39–41 Two variables
were measured by digital image analysis (DIA): (a) integrated
optical density (IOD) measured in pixel units, which is a
measure of the total amount of staining; (b) mean optical
density (MOD), which is a measure of the average density of
staining, equivalent to the concentration of protein per cell. In
addition, these sections were also scored by a semiquantitative
assessment (SQA) method on a five point scale (grades 0–4)
by two independent observers in a random order, as described
previously.36 37
Statistical analysis
Non-parametric statistics were used to analyse the mean
ranks of the SQA scores for the five groups of patients, using a
Kruskal-Wallis one way analysis of variance. As the data for
area,MOD, and IOD,measured by digital image analysis, were
not normally distributed, the data were log transformed and
analysed using a one way analysis of variance. Post hoc differ-
ences between groups were analysed using Tukey HSD and
Bonferroni tests. A value of p<0.05 was considered signifi-
cant.
RESULTS
Clinical and demographic features
Table 1 presents the clinical and demographic data of the
patients with RA and SpA included in the study. The seven
patients with OA included five men and two women, with a
mean age of 67.4 years (range 56–74), four of whom were tak-
ing non-steroidal anti-inflammatory drugs at the time of
synovial tissue removal at knee replacement surgery. The 18
normal subjects included 11 men and seven women, with a
mean age of 33.3 years (range 18–54).
Immunohistochemistry
Figures 1A to D shows that the RANKL expression was
predominantly seen in areas of mononuclear cell aggregates in
the synovial membranes from patients with active RA and
SpA,which are absent in patients with inactive RA, OA, and in
normal subjects. However, although all samples from the
patients with SpA and active RA had active synovitis with
lymphoid infiltrates, staining was variable and many sections
were negative for RANKL expression. RANKL expression was
absent in the RA synovial lining and endothelial cells of the
synovial blood vessels in all groups.
Dual immunohistochemical labelling with RANKL in com-
bination with lineage-specific mAbs for T cells (CD3), B cells
(CD22), macrophages (CD68), and FLS (mAb67), clearly
showed that mAb RANKL 626 stained a subset of pan-T cells
as well as about 40% of macrophages (figs 1E and G). Neither
B cells (CD22) (fig 1F), nor the fibroblasts of the synovial lin-
ing (CD55 (mAb67) positive) (fig 1H), co-localised with
RANKL positive cells. Activated memory T cells (CD45Ro
positive) were abundant in the lymphoid aggregates present
in patients with RA and SpA, whereas few were present in the
control groups. Regions of CD45Ro cells corresponded with
cells both positive and negative for RANKL in sequential sec-
tions (fig 2). In tissue sections from the patients with active
RA up to about 70% of CD45 positive cells corresponded with
cells positive for RANKL. In many cases aggregates of CD45Ro
positive cells were devoid of RANKL staining in the
corresponding areas of sequentially stained sections.
Statistical analysis
Table 2 shows the computer assisted image analysis results
and SQA scores for RANKL detected by mAb 626. Expression
of RANKL as detected bymAb 626 was seen to varying degrees
in all groups of patients. Staining was notably more extensive
staining in patients with RA and SpA with active synovitis at
the time of synovial biopsy (illustrated in fig 1). There was no
significant difference in the RANKL protein expression in the
synovial membrane between each group as measured by the
SQA. However, there was a trend towards increased RANKL in
the groups with active RA and SpA,with some samples graded
as 3 or 4 using SQA, whereas RANKL in patients with OA and
normal subjects was graded as 0 or 1 in all samples. When
assessed with digital image analysis, the total amount of
staining (IOD) for RANKL in patients with inactive RA,
normal subjects, and patients with OA was significantly less
than in those with active RA (p<0.005), although density of
staining (MOD) was not significantly different.
DISCUSSION
Until recently, investigations of bone destruction in RA have
implicated inflammatory cytokines, such as IL1α and β, IL6,
IL11, and TNFα, as the important mediators stimulating bone
lysis.9 10 12 However, there is now mounting evidence that
Table 2 Digital image analysis results (IOD and
MOD) and mean semiquantitative scores for the
expression of RANKL using mAb 626 in synovial tissue
from patients with RA, OA, and SpA and normal
subjects. Data are shown as mean (SD).
mAb626
IOD MOD SQA
Active RA 2426.8 (6524.2) 0.6267 (0.2176) 1 (1.1)
Inactive RA 35.7 (34.6)* 0.6036 (0.1594) 0.2 (0.4)
SpA 702.8 (903.3) 0.6363 (0.2153) 1.1 (1.2)
OA 52.9 (57.7)* 0.6406 (0.2533) 0.4 (0.7)
Normal subjects 55.6 (73)* 0.7653 (0.1650) 0.3 (0.5)
*p<0.005 compared with group with active RA.
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RANKL may be the central mediator of osteoclast develop-
ment in RA and other bone loss pathologies. The focal role of
RANKL is further demonstrated by observation that its natu-
ral inhibitor, OPG, completely prevents cartilage and bone loss
in an arthritic animal model.42 Although it is still likely that
inflammatory mediators present in the RA joint, such as IL1β,
IL6, IL11, and IL17, play a part in stimulating bone lysis, their
major effects may be indirect through stimulation of RANKL
production in the joint.8 14 43
RANK, RANKL, and OPG mRNA are expressed in tissue of
the RA joint, and the levels of RANKL, RANK, and OPG are
believed to determine whether osteoclastogenesis will
occur.5 6 8 The ratio of RANKL to OPG may be a key factor in
determining the level of osteoclastic bone resorption.8 19 44 In
RA, the infiltration of chronic inflammatory cells, which
include macrophages, lymphocytes, and plasma cells, is likely
to contribute to osteolysis, directly through differentiation of
macrophages into osteoclasts and, indirectly, through release
of cytokines that promote osteoclastogenesis and recruitment
of macrophages to the joint. Cell culture studies have shown
that osteoclasts can form from cells with a macrophage
phenotype isolated from the synovium of the RA joint,45 with
large numbers rapidly forming from cells isolated from the
pannus region.8 The differentiation of these cells is RANKL
dependent as demonstrated by its dose dependent inhibition
by OPG.46 Our recent work found that the release of OPG pro-
tein was significantly reduced in synovial biopsy specimens
from patients with active RA compared with control groups.29
This is in accordance with the decreased OPG levels seen in RA
synovial fluid compared with OA as measured with an enzyme
linked immunosorbent assay (ELISA).19
As far as we know, this study is the first to compare RANKL
protein in human synovial tissue from patients with active RA
with that seen in patients with inactive RA, SpAs, OA, and in
normal subjects using SQA and quantitative (DIA) measure-
ment techniques. This study has shown by immunohisto-
chemistry that RANKL protein is absent or in very low levels
in the synovial tissue lining from patients with inactive RA,
OA, and from normal patients. This is in agreement with the
general observations of Kotake et al, who noted that RANKL
positive cells were rare even when OA synovial specimens
contained inflammatory cells.19 In our study, although levels
varied, RANKL was most abundant in the synovial tissue from
patients with RA and SpA with active synovitis. Statistical
assessment of SQA showed that RANKL was not significantly
higher in the RA or SpA groups than in the control groups,
whereas IOD values for RANKL in patients with active RA
were significantly more than in inactive RA, OA and normal
groups. However, SQA grades were designated according to
the proportion of cells, and not the absolute amount of
RANKL protein. Therefore, it is likely that we are underesti-
mating the amount of RANKL in the patients with active RA
using SQA values when compared with the IOD values. This is
supported by previous immunostaining analysis studies, in
which an IOD measurement by DIA was shown to be more
sensitive to change than SQA.36 Although we were unable to
show a significant difference between the groups with active
RA and SpA using the IOD values, these values were on aver-
age markedly lower in the SpA group than in the group with
active RA. Overall, our findings support our original hypoth-
esis that RANKL has an important role in stimulating
osteoclast formation and activity in RA joints where bone loss
occurs.
We detected RANKL protein in mononuclear aggregates
and fibroblast-like cells in the subintimal regions of the syno-
vial membrane. Unlike OPG, RANKL was not expressed on
endothelial cells or in the synovial lining.29 Previous studies
have shown that activated T cells derived from an RA joint
express RANKL mRNA,5 and human activated T cells support
differentiation of adherent murine spleen cells18 and human
monocytes in coculture.19 It is likely that T lymphocytes
support osteoclast differentiation from the many infiltrating
cells of the monocyte/macrophage lineage that migrate to the
inflamed RA joint. Using dual labelling with a CD3 mAb, we
verified that a subset of CD3 positive T cells produces
RANKL.19
Previous studies have not reported the production of
RANKL by activated, memory T cells in human RA. We found
that activated, memory T cells (CD45Ro positive cells) were
present in all patient groups but more abundant in the
lymphoid aggregates of the patients with RA and SpA. This is
in accordance with Sakkas et al, who demonstrated CD45Ro
positive cells in OA and RA patient groups, with higher num-
bers in the RA group.47 A more recent study showed that the
high number of CD45Ro and CD68 cells in patients with active
RA was reduced in patients attaining clinical remission.48
Sequential staining showed that RANKL coincided with some,
but not all, CD45Ro positive cells. This suggests that there are
two subpopulations of CD45Ro positive cells that can be
distinguished from each other based on their ability to
produce RANKL.
The role of B cells in the inflammatory process and bone
lysis in RA remains unclear. More recently it has been
suggested, using an animal model of inflammatory arthritis,
that B lymphoid lineage cells may be able to support
osteoclastogenesis through production of RANKL.49 However,
our results obtained with human synovial tissue do not
support a role for B cells in the production of RANKL as we
could not show that RANKL protein was associated with CD22
positive cells.
Previous in vitro studies have shown that cultured synovial
fibroblasts, extracted from patients with RA, stimulated with
1,25-dihydroxyvitamin D3, can support osteoclast formation
through RANKL expression.6 Occasionally, we noted spindle
shaped cells expressing RANKL protein, as also seen by
Kotake et al.19 However, in our study cells expressing the
fibroblastic cell marker, CD55, did not label with the antibody
detecting RANKL protein. Although it is possible that CD55 is
not expressed on all fibroblastic cells,we believe that our study
supports the contention that activated T lymphocytes, not
fibroblasts, are the major cell type that supports osteoclast
formation by expressing RANKL in the synovial tissue of
patients with active RA.
The current consensus is that monocytes and macrophages
are not a major source of RANKL. However, we did observe
many cells expressing the macrophage marker CD68 that also
expressed RANKL.Without in situ hybridisation we could not
verify whether these cells were the source of RANKL or merely
binding RANKL that was produced by other cells. However,
evidence that these cells can produce RANKLwas presented in
our previous reports that show that human adherent periph-
eral blood mononuclear cells in cell culture can express
RANKL mRNA when stimulated by prosthetic wear debris.44
Horwood et al also noted macrophage-like cells expressing
RANKL mRNA in RA tissue.18
We now have a better understanding of the potential proc-
esses and cells involved in joint destruction in RA. In our pre-
vious work we showed that OPG is present in endothelial and
type A synovial lining cells in the synovial membrane of
patients with RA.29 In this study we demonstrated that
RANKL protein is associated with macrophages and a subset
of CD3 and CD45Ro positive T cells but not B cells or endothe-
lial cells in the RA synovial membrane. The absence of OPG in
active RA synovial tissue reported in our previous study, and
the significantly higher levels of RANKL in the same tissue
demonstrated in this study, show that these molecules are
likely to be key regulators of bone loss in active RA. The rela-
tive levels of both RANKL and OPG are likely to be important
in determining the levels of bone loss in health and disease.
OPG is not present in patients with active disease, suggesting
that OPG expression may regulate bone loss in RA. This study
showed that the highest levels of RANKL protein expression
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are seen during active disease, further supporting the hypoth-
esis that the extent of bone resorption is largely determined by
the relative amounts of RANKL compared with OPG in RA.
This identifies OPG/RANKL/RANK pathways as important
future therapeutic targets to treat joint destruction in RA.
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ONLINE SUBMISSION....................................................................................
New ARD online submission and review system
We are pleased to inform authors and reviewers of ARD’s newonline submission and review system: Bench Press. This is afully integrated electronic system which uses the internet to
allow rapid and efficient submission of manuscripts, and the entire
peer review process to be conducted online.
Authors can submit their manuscript in any standard word process-
ing software. Graphic formats acceptable are: .jpeg, .tiff, .gif, and .eps.
Text and graphic files are automatically converted to PDF for ease of
distribution and reviewing purposes. Authors are asked to approve their
submission before it formally enters the reviewing process.
To access the system click on “SUBMITTING YOURMANUSCRIPT”
on the ARD home page: http://www.annrheumdis.com/, or you can
access Bench Press directly at http://submit-ard.bmjjournals.com/.
We are very excited with this new development and we would
encourage authors and reviewers to use the online system where pos-
sible. It really is simple to use and should be a big improvement on the
current peer review process. Full instructions can be found on Bench
Press and ARD online.
Please contact Natalie Davies, Project Manager,
ndavies@bmjgroup.com for further information.
Pre-register with the system
We would be grateful if all ARD authors and reviewers pre-registered
with the system. This will give you the opportunity to update your




2 Click on “Create a new account” in the upper left hand side of the
Bench Press home page
3 Enter your email address in the space provided
4 Choose a password for yourself and enter it in the spaces
provided
5 Complete the question of your choice to be used in the event you
cannot remember your password at a later time (this will be
needed if you forget your password)
6 Click on the “Complete step 1” button at the bottom of the screen
7 Check the email account you registered under. An email will be
sent to you with a verification number and URL.
8 Once you receive the email, copy the verification number and
click on the URL hyperlink. Enter the verification number in the
relevant field. Click on “Verify me”. This is for security reasons
and to check that your account is not being used fraudulently.
9 Enter/amend your contact information, and update your expertise
data.
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